| Market Capitalization (Millions $) |
730 |
| Shares
Outstanding (Millions) |
58 |
| Employees |
14 |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-124 |
| Cash Flow (TTM) (Millions $) |
15 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Astria Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing drugs for the treatment of cancer and other diseases. The company was founded in 2018 and is headquartered in San Francisco, California.
Astria Therapeutics has developed an innovative platform technology that enables the company to develop targeted therapies that can selectively kill cancer cells while sparing healthy cells. The company's technology uses a proprietary approach to deliver cancer treatments directly to tumor cells, which can potentially reduce the side effects associated with traditional chemotherapy and radiation therapy.
The company's lead drug candidate, AST-008, is being developed for the treatment of solid tumors. AST-008 is a small molecule inhibitor that targets a specific protein known as CDC7, which is involved in the regulation of DNA replication. By targeting CDC7, AST-008 can prevent cancer cells from dividing and multiplying, which can ultimately lead to their death.
Astria Therapeutics has also developed a pipeline of other drug candidates that are being developed for the treatment of various types of cancer, including breast cancer, lung cancer, and pancreatic cancer. The company's pipeline includes both small molecule inhibitors and antibody-drug conjugates (ADCs), which are designed to selectively deliver drugs to cancer cells.
In addition to its cancer drug development programs, Astria Therapeutics is also developing drugs for the treatment of inflammatory and autoimmune diseases. The company's lead drug candidate for these indications is a small molecule inhibitor of a protein called CCR5, which is involved in the immune response.
Astria Therapeutics has received funding from several leading venture capital firms, including F-Prime Capital, Boxer Capital, and Novo Holdings. The company's management team includes experienced executives with years of experience in the biopharmaceutical industry, including CEO Weidong Zhong, who previously served as the Chief Scientific Officer of Tesaro, Inc., a pharmaceutical company that was acquired by GlaxoSmithKline in 2018.
Company Address: 22 Boston Wharf Road 10th Floor Boston 2210 MA
Company Phone Number: 349-1971 Stock Exchange / Ticker: NASDAQ ATXS
|
6.46% 
100 %